GET DAILY SIGNALSClaritev Corporation (CTEV): Analyst Targets Imply +90% Potential Upside
Key Takeaways
- The central target of $46 reflects the arithmetic mean of five analyst price targets from Barclays, Piper Sandler, Wells Fargo, Canaccord Genuity, and Citi.
- With Claritev Corporation (CTEV) shares near $24, reaching $46 would mean an advance of about 90%, a substantial move.
- Analyst targets range widely from $30 to $73, highlighting real differences in views on the firm’s high leverage and turnaround efforts.
- Positive elements include six straight quarters of revenue growth, a $1 billion trailing twelve-month revenue milestone, and increased full-year guidance.
- The main concern remains a net leverage ratio around 7.7x along with ongoing GAAP losses that limit room for setbacks.
- Investors can check Major News, Today's Price Move, the AI-driven Forecast, and Earnings pages for CTEV.
Analyst Price Targets and Consensus View
Claritev Corporation (CTEV), previously known as MultiPlan Corporation, delivers data-analytics and technology-enabled cost-management, payment, and revenue-integrity solutions for the U.S. healthcare sector. The central target of $46 comes from averaging five sell-side estimates: Barclays at $40, Piper Sandler at $73, Wells Fargo at $30, Canaccord Genuity at $43, and Citi at $45. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $30-to-$73 spread stands out as unusually broad and points to differing opinions. Optimistic voices, such as Piper Sandler’s $73 target, highlight faster revenue growth, solid bookings, and margin progress. More measured views, including Wells Fargo’s Hold-rated $30 target, center on elevated debt and negative GAAP EPS. Most firms carry Buy or equivalent ratings, yet the dispersion suggests the average should not be treated as a firm prediction.
Current Market Position and Path Toward the Target
Shares of CTEV trade near $24, well below the 52-week high of about $73 and above the 52-week low near $11.50. Reaching $46 would require roughly 90% appreciation, a sizable move. In my view, getting there would most likely call for sustained mid-to-high single-digit revenue growth, further balance-sheet deleveraging, and renewed expansion in the Payment & Revenue Integrity segment in 2027, plus a higher valuation multiple.
What Could Support a Move Toward the Target
Third-quarter 2026 revenue came in at $268.3 million, up 9.1% year over year. That marked the sixth consecutive quarter of growth and the highest quarterly revenue in 17 quarters. Trailing twelve-month revenue crossed $1 billion for the first time since early 2023. Management lifted full-year 2026 revenue guidance to about $1.04 billion and adjusted EBITDA to $625-$630 million, while signaling at least $1.1 billion of revenue in 2027. Annualized contract value bookings are rising sharply, and the company is broadening beyond payer clients. These trends support the more bullish end of the range.
What Could Prevent the Target From Being Reached
The balance sheet remains the chief hurdle. Net leverage stood near 7.7x at quarter-end, and the company continues to post GAAP net losses, including a Q3 2026 net loss of $61.8 million and GAAP EPS of negative $3.64. Adjusted EBITDA margin slipped to 60.4% from 63.1% a year earlier, and free cash flow stayed negative amid higher capital spending. The Payment & Revenue Integrity segment is trailing internal plans as clients move toward Claims Intelligence solutions. High leverage, persistent losses, and margin pressure could all limit valuation multiples and keep the stock short of the average target.
Technical Levels and Market Structure
The 52-week range of roughly $11.50 to $73 underscores notable volatility. At around $24, CTEV sits in the lower half of that band, with the $46 target about midway between the current price and the prior high. Round-number areas near $25 and $30 may serve as intermediate resistance, while zones near $20 and the prior low offer potential support. The longer-term pattern looks like a wide, choppy trading range rather than a steady uptrend.
Time Horizon and What Investors Should Monitor
Analyst targets typically cover a roughly 12-month horizon, though individual firms vary and no single timeframe was stated uniformly. I’m watching quarterly earnings and guidance updates, any shifts in leverage or refinancing plans, bookings and new-client announcements, and analyst target revisions, which have been frequent and sizable for this name. The wide range means moves in either direction could meaningfully alter the consensus picture.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my own research process I turn to Tickeron’s AI Daily Buy/Sell Signals to monitor thousands of stocks and ETFs. The tool applies artificial intelligence to track changing market conditions and technical behavior, producing Buy, Sell, or Hold signals that help spot opportunities and shifting trends more efficiently than manual checks alone. I find it useful for confirming ideas generated from traditional analysis before making decisions.
Final Assessment
The $46 central target is the average of five analyst estimates and points to roughly 90% upside from levels near $24. That remains a large move, and the $30-to-$73 spread shows analysts themselves hold sharply different views on the outlook. The bull case rests on reaccelerating revenue, record bookings, and raised guidance, while the bear case focuses on 7.7x leverage, ongoing GAAP losses, and margin compression. Whether CTEV reaches $46 will likely hinge most on sustained top-line momentum and real balance-sheet improvement. No outcome is assured.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CTEV in -12.50% downward trend, declining for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CTEV declined for three days, in 272 of 297 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for CTEV entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CTEV's RSI Oscillator exited the oversold zone, 32 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 54 cases where CTEV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CTEV as a result. In 59 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CTEV just turned positive on October 08, 2026. Looking at past instances where CTEV's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
Following a +18.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTEV advanced for three days, in 224 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CTEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.307) is normal, around the industry mean (4.477). P/E Ratio (-1.336) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.562) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. CTEV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry